COMPOSITIONS COMPRISING VITAMIND LUMISTEROLANALOG PRECURSORS
This application is a continuation of application Ser. No. 07/935,471, filed Aug. 27, 1992 , now abandoned, which is a continuation of application Ser. No. 07/593,934, filed Oct. 4, 1990 , now abandoned.
FIELD OF THE INVENTION
The invention is in the field of cosmetics and medici nal chemistry. In particular, the present invention re lates to topical compositions which provide vitamin D analogs throughout the year. In another aspect, the present invention relates to a method of producing pre vitamin D analogs. The topical compositions of the invention allow a user in the northern latitudes to pro duce previtamin D analogs on their skin even when exposed to low energy sunlight in the winter as well as in the morning and evening throughout the year. The method employs tachysterol and lumisterol analogs which photoisomerize to previtamin D analogs when exposed to low levels of ultraviolet radiation.
BACKGROUND OF THE INVENTION
Vitamin D3 is a derivative of provitamin D3 (7- tude, geographical location, time of day and area of exposure to sunlight. Common to most of these factors is the availability of the requisite amount of ultraviolet radiation with energies between 290 and 315 nm which is necessary to convert provitamin D3 to vitamin D3. MacLaughlin et al., Science 216:1001 -1003 (1982 .
The availability of vitamin D precursor in the skin and its photo-induced transformation to previtamin D3 and then to vitamin D3 is an efficient physiological source of and mechanism for the replenishment of vita min D3. However, during the winter in northern lati tudes, sunlight does not contain enough high energy ultraviolet radiation to convert provitamin D3 (7-dehy drocholesterol) in human skin to previtamin D3 (Webb, Kline and Holick, J. Clin. Endocrinol Met. 67:373-378 (1988) . As a result, individuals in these latitudes cannot make vitamin D3 in their skin, even when they are ex The availability of the vitamin D precursor in the skin and its photo-induced transformation to previtamin D3, and then to vitamin D3, is an efficient physiological source of, and mechanism for the replenishment of vita min D3. Previously, it was thought that the only method of producing previtamin D3 was to transform provitamin D3. This transformation requires sunlight or artificial UV light in the region of 290-315 nm. There fore, in areas where the available light energy is below this range (wavelengths greater than 316 nm), the trans formation does not occur to any significant extent. Kobayashi et al., J. Nutr. Sci Vitaminol. 19:123 (1973 MacLaughlin et al., Science 216:1001 Science 216: -1003 Science 216: (1982 , disclose the synthesis of previtamin D3 from provitamin D3 in human skin and in an organic solvent after expo sure to narrow-band-radiation or simulated solar radia tion. When human skin or an organic solvent containing provitamin D3 were exposed to 295 nm radiation, up to 65% of the provitamin D3 was converted to previtamin D3. The authors further disclose that the optimum wavelength for the production of previtamin D3 is be tween 295 nm and 300 nm.
Dauben et al., J. Ann. Chem. Soc. 104:5780-5781 (1982) ; J. Am. Chem. Soc. 104:355-356 (1982) , disclose the effect of wavelength on the photochemistry of pro vitamin D3 and the effect of wavelength on the produc tion of previtamin D3. The authors found that when provitamin D3 is exposed to light in the range of 254 nm, it is converted to a variety of photoproducts, the major portion being about 75% tachysterol. This mixture was then exposed to either 300 nm of light, broad-band 350 nm light or 355 nm light to give a build up of previtamin D3. Dauben et al. conclude Holicket al. disclose that the photochemical conver sion of previtamin D3 to lumisterol and tachysterol is the major factor that prevents vitamin D3 intoxication after a single prolonged exposure to the sun. Holicket al., Science 211: 590-592 (1981) . The corollary to this finding is that lumisterol and tachysterol are two bio logically inert products thought to be sloughed off the skin during the natural turnover of the epidermal cells.
Provitamin D2 (ergosterol) is the precursor of vita min D2. Vitamin D2 is one of the major forms of vitamin D that is used to fortify foods such as milk and mul tivitamins.
SUMMARY OF THE INVENTION
The present invention is related to the discovery that topical formulations comprising lumisterol and tachys terol analogs are effective means of providing previta min D analogs to individuals. The present invention utilizes the low energy UV photoconversion of lumis terol and tachysterol analogs to previtamin Danalogs as a method of producing vitamin D analogs in the skin. It is this novel finding that solves the problem of produc ing vitamin D analogs via the skin in areas of low en ergy Sunlight.
In particular, the invention is directed to lumisterol and tachysterol analogs which are convertible to vita min D analogs in the presence of low energy UV light. The invention is also directed to pharmaceutical com positions containing an effective amount of lumisterol and or tachysterol analogs and a pharmaceutically ef fective carrier.
The invention is also directed to a method for provid ing vitamin D analogs to an individual by administering to the individual a pharmaceutical composition of the invention.
The invention is also directed to a method of treating hyperproliferative disorders of the skin including psori asis, healing wounds and inhibiting scar formation with 45 the pharmaceutical compositions of the invention. When the bond between C-22 and C-23 is a single covalent bond and X is hydrogen, the compounds belong to the D3 family, e.g. vitamin D3. Where the bond between C-22 and C-23 is a double covalent bond and X is methyl, the 60 compounds belong to the D2 family, e.g. vitamin D2.
FIGS. 2(A and B) depict an HPLC trace of a control solution of provitamin D3 (A) and a solution of provita min D3 exposed to sunlight on a day during the winter (B).
FIGS. 3(A and B) depict an HPLC trace of a control solution of tachysterol (A) and a solution of tachysterol exposed to sunlight on a day during the winter (B). FIGS. 4(A and B) depict an HPLC trace of a control solution of lunisterol (A) and a solution of lumisterol exposed to sunlight on a day during the winter (B).
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention provides for a method of heal ing wounds and inhibiting scar formation and treating hyperproliferative disorders of the skin including psori asis. Wounds to the external epithelium include cuts, punctures and lacerations, including corneal lacera tions. The invention also provides for the treatment of ulcers such as diabetic ulcers of the feet, decubitus ul cers (bed sores), genito-urinary ulcers, and ulcerative keratitis. Ulcerative keratitis is caused, for example, by extended wear of contact lenses. Biochem. 18:1003 Biochem. 18: -1008 Biochem. 18: (1979 , which is fully incor porated by reference herein.
Examples of tachysterol and lumisterol analogs in clude 1-hydroxytachysterol2, 1-hydroxytachysterol3, 1-hydroxylumisterol.2, 1-hydroxylumisterol3, 1,24-dihy droxytachysterol.2, 1,24-dihydroxytachysterol3, 1,24 dihydroxylumisterol.2, 1,24-dihydroxylumisterols, 1,25 dihydroxytachysterol2, 1,25-dihydroxytachysterol3, 1, 25-dihydroxylumisterol.2, 1,25-dihydroxylumisterol3, 24,25-dihydroxytachysterol2, 24,25-dihydroxytachys terol3, 24,25-dihydroxylumisterolz, 24,25-dihydrox ylumisterol3, 25,26-dihydroxytachysterol.2, 25,26-dihy droxytachysterols, 25,26-dihydroxylumisterol, 25,26 dihydroxylumisterol3, 1,24,25-trihydroxytachysterol.2, 1,24,25-trihydroxytachysterol3, 1,24,25-trihydrox ylumisterolz, 1,24,25-trihydroxylumisterol3, 2-g-(3-hydroxypropoxy)-1 alpha,25-dihydroxytachysterol.2, 2-6-(3-hydroxypropoxy)-1 alpha,25-dihydroxytachys terol3, 2-g-(3-hydroxypropoxy)-1 alpha,25-dihydrox ylumisterol2, 2-6-(3-hydroxypropoxy)-1 alpha,25-dihy droxylumisterol3, as well as the side chain fluoro deriva tives of 1,25-dihydroxytachysterol2, 1,25-dihydroxyta chysterois, 1,25-dihydroxylunisterol.2, 1,25-dihydrox ylumisterol3, 1-hydroxytachysterol.2, 1-hydroxytachys terol3, 1-hydroxylumisterol2, and 1-hydroxylumisterol3. Also included are the 20-and 22-oxa tachysterol and lumisterol derivatives including 20-oxa-1a(OH)tachys 25(OH)2tachysterol3, 25(OH)2lumisterol2, 25 (OH)-2lumisterol3, 22-oxa-1a(OH)tachysterol2, 22-oxa 1a(OH)tachysterol3, 22-oxa-1a(OH)lumisterol, 22 oxa-1a(OH)lumisterol3, 22-oxa-1a,25(OH)2tachys terol.2, 22-oxa-la,25(OH)2tachysterols, 22-oxa-1a,2-5(OH)2lumisterola and 22-oxa-1a,25(OH)2lumisterol3. Also included within the scope of the present invention are 25,26 cyclopropyl compounds including 1,24-dihy droxy-25,26-dehydrotachysterol3, 1,24-dihydroxy 25,26-dehydrotachysterol.2, 1,24-dihydroxy-25,26-dehy drolunisterol3, and 1,24 -dihydroxy-25,26-dehy drolumisterol.2. Foremost among the individuals which may be treated with the compositions of the invention are hu mans, although the invention is not intended to be so limited. Any animal which may benefit from treatment with the compositions of the invention are within the spirit and scope of the present invention.
By using tachysterol and lumisterol analogs in topical compositions according to this invention, it is possible for the first time to provide a method which allows individuals living in regions of low sunlight to produce vitamin D analogs via their skin. The compositions of the present invention may be used, therefore, in meth ods of treating decubitus and diabetic foot ulcers; ulcer ative keratitis; treating psoriasis; wound healing; inhibit ing scar formation; treating or preventing osteodystro phy due to an acquired or inherited disorder in vitamin D metabolism; glucocorticoid-induced decrease in cal cium absorption; osteoporosis; senile decrease in cal cium absorption; hypoparathyroidism; milk fever dis ease; and turkey weak leg disease.
The compounds of the present invention can be ad ministered in any appropriate pharmacological carrier for topical or intravenous administration. The dosage administered will be dependent on the age, health and weight of the recipient, and the nature of the effect desired.
The topical compositions of the invention may be applied so that at least 0.1 microgram, preferably at least about 10 micrograms to about 100 mg of the vita min D precursor/gm carrier is administered to the skin.
A preferred range is between about 1 microgram to about 1 milligram of tachysterol analog or lumisterol analog/gm carrier.
The compositions of the invention formulated for intravenous administration may comprise at least about 0.1 microgram, preferably at least about 1.0 microgram to about 100 mg of the vitamin D precursor per ml of physiologically acceptable solution. A most preferred range is about 1.0 micrograms to about 100 micrograms of tachysterol analog or lunisterol analog per ml of solution.
The compounds can be employed in a pharmacologi cally inert topical carrier such as one comprising a gel, an ointment or a cream, including such carriers as wa ter, glycerol, alcohol, propylene glycol, fatty alcohols, triglycerides, fatty acid esters or mineral oils. Other possible carriers are liquid petrolatum, isopropylpalmi tate, polyethylene glycol ethanol 95%, polyoxyethyl ene monolaurate 5% in water, sodium laurylsulfate 5% in water, and the like. Minerals such as anti-oxidants, humectants, viscosity stabilizers and the like may be added, if necessary. 7 Alternatively, the compounds may be employed as part of a sun screen lotion which selectively screens the harmful high energy UV radiation (below 315 nm) but which allows medium and low energy UV radiation (above 315 nm) to pass which is of sufficient energy to photoisomerize lumisterol and tachysterol analogs to previtamin D analogs. Alternatively, the lumisterol and tachysterol analogs may be added to broad range sun screens that absorb radiation with energies of up to 360 nm. Such sun screen lotions may comprise any of those well known to those of ordinary skill in the art, for example, ethyl p-aminobenzoate (benzocaine), p aminobenzoic acid (PABA), octyl methoxycinnamate (PARASOL (R) MCX), butyl methoxydibenzoylme thane (PARASOL (R) 1789), phenyl salicylate (salcol), 2-ethoxyethyl p-methoxycinnamate, glyceryl p aminobenzoate, 2,4-dibenzoyl resorcinol, octyl di methyl PABA, oxybenzone, benzophenones, methyl anthranilate, cinoxate, amyldimethyl PABA, homo menthyl salicylate, digalloyl trioleate, ethyl-pglycosylimido benzoate, and red veterinary petrolatum. 17: 628-634 (1978) , Sayre, R. M. et al., Photochem. Photobiol. 29:559-566 (1979) .
Preparations for parenteral administration include sterile or aqueous or non-aqueous solutions, suspen sions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, al coholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutri ent replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, anti-oxidants, chelating agents, inert gases and the like. See, generally, Remington's
